Rezolute, Inc.

NASDAQ:RZLT

Biotechnology

Healthcare
$4.25 +6.16%

+$0.30 today

Market cap
$411.10M
Beta
0.65
P/E (TTM)
-6.5
EPS (TTM)
-$0.78
52W Low $1.07High $11.46

Volume 2.93M

Average 2.03M

RZLT EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Rezolute, Inc.NASDAQ: RZLT

EBITDA · Q3 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q3 FY2026 EBITDA was -$16.16M, compared with -$18.91M a year earlier. Trailing-twelve-month EBITDA was -$81.45M.

Context

  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 6 analysts of $0 (+100.0%) for the fiscal year ending Jun 2026, a step up from the -8.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$16.16M+29.0% QoQ
Last fiscal yearJun 2025
-$74.38M-8.7% YoY
LTMMar 2026
-$81.45M-11.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.5%+100.0%+85.5 pp
1 year-8.7%+100.0%+108.7 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(74.38M) USD
Year-over-year change
-8.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How RZLT compares with its peers on the latest reported figures

  • RZLT's LTM Mar 2026 EBITDA of -$81.45M is the 4th highest of the 5 companies compared; the peer median is $5.71M.
  • Its year-over-year change of -11.6% is the 4th highest of 5, against a peer median of +63.3%.
RZLT Competitors Peer median
EBITDA for RZLT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$140.47M +332.9%—114.9%
PHARPharming Group N.V.LTM Mar 2026$39.48M +82.4%-1.9%10.7%
RLYBRallybio CorporationLTM Mar 2026-$28.06M +44.2%—3270.4%
RZLTRezolute, Inc.LTM Mar 2026-$81.45M -11.6%——
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-$503.35M -11.9%—75.2%
Peer median (excluding RZLT) $5.71M+63.3%-1.9%95.0%

Competitors are the stored peer set for RZLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue00000
Cost of Revenue13K0000
Gross Profit(13K)0000
Gross Margin—————
Research & Development14.99M32.49M43.81M55.74M61.53M
Selling, General & Admin7.91M9.36M12.18M14.68M18.37M
Operating Expenses22.88M41.84M55.99M70.42M79.89M
Depreciation & Amortization13K13K30K36K31K
EBITDA(20.51M)(39.24M)(51.76M)(68.42M)(74.38M)
EBITDA Margin—————
Operating Income(22.89M)(41.84M)(55.99M)(70.42M)(79.89M)
Operating Margin—————
Interest Income63K80K4.21M4.87M5.48M
Interest Expense375K1.81M000
Other Income / Expenses1.99M783K4.2M1.96M5.48M
Income Before Tax(20.9M)(41.06M)(51.79M)(68.46M)(74.41M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(20.9M)(41.06M)(51.79M)(68.46M)(74.41M)
Net Margin—————
EPS (Basic)(2.72)(2.26)(1.01)(1.33)(0.98)
EPS (Diluted)(2.72)(2.32)(1.01)(1.33)(0.98)
Weighted Avg Shares7.67M18.2M51.19M51.47M76M
Weighted Avg Shares (Diluted)7.67M19.49M51.19M51.47M76M

Rezolute, Inc.

NASDAQ:RZLT

Intrinsic Alpha fair value

Locked

Current Price

$4.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.